0001768185-20-000001.txt : 20201021 0001768185-20-000001.hdr.sgml : 20201021 20201021160353 ACCESSION NUMBER: 0001768185-20-000001 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20201021 DATE AS OF CHANGE: 20201021 EFFECTIVENESS DATE: 20201021 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Chinook Therapeutics U.S., Inc. CENTRAL INDEX KEY: 0001768185 IRS NUMBER: 832535029 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-378507 FILM NUMBER: 201250602 BUSINESS ADDRESS: STREET 1: 1600 FAIRVIEW AVE. E. CITY: SEATTLE STATE: WA ZIP: 98102 BUSINESS PHONE: 604-343-1552 MAIL ADDRESS: STREET 1: 1600 FAIRVIEW AVE. E. CITY: SEATTLE STATE: WA ZIP: 98102 D 1 primary_doc.xml X0708 D LIVE 0001768185 Chinook Therapeutics U.S., Inc. 1600 FAIRVIEW AVE. E. Suite 100 SEATTLE WA WASHINGTON 98102 206-485-7051 DELAWARE None None Corporation true 2018 Eric Dobmeier c/o Chinook Therapeutics U.S., Inc. 1600 Fairview Ave. E., Suite 100 Seattle WA WASHINGTON 98102 Executive Officer Director Alan Glicklich c/o Chinook Therapeutics U.S., Inc. 1600 Fairview Ave. E., Suite 100 Seattle WA WASHINGTON 98102 Executive Officer Tom Frolich c/o Chinook Therapeutics U.S., Inc. 1600 Fairview Ave. E., Suite 100 Seattle WA WASHINGTON 98102 Executive Officer Andrew King c/o Chinook Therapeutics U.S., Inc. 1600 Fairview Ave. E., Suite 100 Seattle WA WASHINGTON 98102 Executive Officer Jerel Davis c/o Chinook Therapeutics U.S., Inc. 1600 Fairview Ave. E., Suite 100 Seattle WA WASHINGTON 98102 Director Jeremy Caldwell c/o Chinook Therapeutics U.S., Inc. 1600 Fairview Ave. E., Suite 100 Seattle WA WASHINGTON 98102 Director Paul Eisenberg c/o Chinook Therapeutics U.S., Inc. 1600 Fairview Ave. E., Suite 100 Seattle WA WASHINGTON 98102 Director Srinivas Akkaraju c/o Chinook Therapeutics U.S., Inc. 1600 Fairview Ave. E., Suite 100 Seattle WA WASHINGTON 98102 Director Preston Klassen c/o Chinook Therapeutics U.S., Inc. 1600 Fairview Ave. E., Suite 100 Seattle WA WASHINGTON 98102 Director Biotechnology Decline to Disclose 06b false 2020-08-17 false true false Immediately after the closing of this transaction, the Company completed its merger into Aduro Biotech, Inc. 0 115000000 115000000 0 false 25 0 0 0 false Chinook Therapeutics U.S., Inc. /s/ Eric Dobmeier Eric Dobmeier President and Chief Executive Officer 2020-10-21